Navigation Links
Essilor Cancels 1,600,000 Shares
Date:12/2/2008

CHARENTON-LE-PONT, France, December 3 /PRNewswire-FirstCall/ -- On November 28, Essilor cancelled 1,600,000 shares, in line with its commitment to shareholders to offset the dilutive impact of Oceane bond conversions and the Company's stock option plans.

These latest cancellations concerned shares acquired under the 6.9 million share buyback program authorized by the Board of Directors on July 15, 2008 to offset the dilutive impact of converting outstanding Oceane bonds due in 2010. To date, a total of 1.5 million shares have been bought back under this program.

At the same time, in line with its standard practice, Essilor has cancelled shares bought back on the market in order to offset the dilutive impact of its stock option plans, and also of its performance share plans which are covered by shares held in treasury stock.

Following these cancellations, Essilor's capital is represented by 210,445,678 shares.

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Essilor(R) and Definity(R) brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 270 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index (ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EF FP).

    Investor Relations and Financial Communications
    Phone: +33(0)1-49-77-42-16
   http://www.essilor.com


'/>"/>
SOURCE Essilor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Essilors 2007 Third-Quarter Report
2. Essilor Cancels 700,000 Shares
3. Essilor: New Acquisitions in the United States and Brazil
4. Essilor : Nomination of Hubert Sagnieres
5. Essilors First-Half 2008 Results
6. Essilor Finalizes Satisloh Agreement
7. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
10. Neuralstem Shares Accepted for Trading on Amex(R)
11. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Renowned Clinical Authorities to Advise on Development of New Drug ... Candidate to Treat Autoimmune Disease ... a privately-held drug development company, announced today that it,has appointed ... a peptide fusion protein licensed from Amgen in December 2007 ...
... Merchandisers to Sell Unique Back and Other Pain ... ... Sheets: BIEL), announced today that it has signed a,sales, marketing and distribution ... leading Canadian sales and marketing,distributor of natural health products, medical devices, and ...
... BRISBANE, Australia, Feb. 5 Xenome Limited today,announced ... Company,s Chief,Executive Officer. Dr. Nisbet will also join ... previously worked in senior management and executive,roles in ... Meditech Research Ltd, Millennium Pharmaceuticals Inc,and CSL Ltd. ...
Cached Biology Technology:Anthera Pharmaceuticals Forms Scientific Advisory Board 2BioElectronics Announces Canadian Retail Product Launch 2Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer 2
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... researchers led by Richard Van Emmerik at the University ... through the Navy Health Research Center in the Department ... load carried by soldiers, which can be even heavier ... and ability to carry out missions. "Load is ...
... This press release is available in German . ... tunicate maize, the maize kernels on the cob are not ,naked, ... scientists from the Max Planck Institute for Plant Breeding Research in ... the activity of a leaf gene in the maize cob that ...
... /PRNewswire-iReach/  -- Global Information Inc. is announces limited time ... important Boston healthcare conferences: Next-Gen Kinase ... rapidly maturing kinase inhibitors field will gather to explore ... Next-Gen Kinase Inhibitors Conference in Cambridge, MA. ...
Cached Biology News:Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2Pod corn develops leaves in the inflorescences 2Pod corn develops leaves in the inflorescences 3Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3
... flask clips, purpose-designed to firmly retain glassware, ... are equipped with a top retainer spring; ... bottom retainer spring, and silicon tubing spring ... Clips include the required mounting screws., ...
... shaker flask clips, purpose-designed to firmly retain ... clips are equipped with a top retainer ... a bottom retainer spring, and silicon tubing ... glassware. Clips include the required mounting ...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... Heavy duty stainless-steel shaker flask clips, purpose-designed ... speeds. All clips are equipped with ... 1L.) also include a bottom retainer spring, ... scratching of expensive glassware. Clips include ...
Biology Products: